Sodium-glucose cotransporter 2 inhibitors in lipotoxicity correction Gogoleva S.P.
AbstractAdipokines are involved in the regulation of almost all processes in the body. Their production impairment and excessive accumulation of free fatty acids lead to the development of lipotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may affect both carbohydrate and fat metabolism. That represents scientific and practical interest.
Keywords:leptin, adiponectin, type 2 diabetes mellitus, lipotoxicity
Funding. The study had no sponsor support.
Conflict of interests. The author declare no conflict of interests.
For citation: Gogoleva S.P. Sodium-glucose cotransporter 2 inhibitors in lipotoxicity correction. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (3): 67-9. DOI: https://doi.org/10.33029/2304-9529-2020-9-3-67-69 (in Russian)
References
1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. 2019.
2. Russian Federal State Statistics Service. http://www.gks.ru (date of access January 15, 2019) (in Russian)
3. Bhupathiraju S.N., Hu F.B. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118 (11): 1723-35.
4. Ametov A.S., Tertychnaya E.A. Insulin resistance and lipotoxicity are two facets of the same problem in type 2 diabetes and obesity Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 2 (27): 25-33. (in Russian)
5. European Medicines Agency. Forxiga 5 and 10 mg film-coated tablets: summary of product characteristics. 2012.
6. Kawata T., Iizuka T., Iemitsu K., et al. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus. J Clin Med Res. 2017; 9 (7): 586-95.
7. Hideka I., et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019; 10 (4): 1012-21.
8. Wu P., Wen W., Li J., et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res. 2019; 51 (8): 487-94.